SecBot SecBot

WVE

Wave Life Sciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. U0· CIK 0001631574 Biotech & Drug Discovery
$2.87 −0.26 (−8.31%)
Nov 16 4:00 PM ET · prev $3.13
Market cap
$622.3M
Small cap
Consensus
Buy
92% Buy or better · 25 analysts
Median target
$14.00
+388% · range $10.00–44.00
1 year
−59.9%
from $7.15 · Nov 17
30 days
−9.5%
from $3.17
52-week range
$2.87–21.31
at the low
Avg volume 20D
2.97M
shares / day
Short interest
20.65M
≈10.5% of shares · −2.5%
Days to cover
6.8
at average volume
Insider net
+$53.7M
1 buyer · 8 sellers · 12 mo
New fund stakes
3
Q3 2026 13F · 8 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $54.6M at an average $6.23. 8 insiders sold $892.6K. Price is 54% below their cost.

  • InstitutionsBEARISH

    Q3 2026: 5 added (3 new), 8 trimmed or exited. Largest new: Marshall Wace $13.6M, Ubs Group Ag $10.7M.

  • AnalystsBULLISH

    23 of 25 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −2.5% to 20.65M shares. 6.8 days to cover, ≈10.5% of shares.

  • TrendRANGE

    22% below its 50-day average. New closing low $2.87 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 3.

Who's buying

13F· Q3 2026
3
new positions
8
exits
$34.7M
in new stakes
FundMoveSharesValue
Qube Research & Technologies LtdADD3,675,358$13.6M
MARSHALL WACE, LLPNEW3,663,275$13.6M
UBS Group AGNEW2,895,681$10.7M
Aberdeen Group plcNEW2,819,129$10.4M
MORGAN STANLEYEXIT0$0.00
Squarepoint Ops LLCEXIT0$0.00
VANGUARD CAPITAL MANAGEMENT LLCEXIT0$0.00
VANGUARD PORTFOLIO MANAGEMENT LLCEXIT0$0.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

25 analysts
Buy 92% rate it Buy or better
Strong Buy9Buy14Hold2Sell0Strong Sell0
12-month targets · 19 analysts

Price is below the lowest target. Median implies +388%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 9, 2026B. Riley Securities
REITERATE
REITERATEBuy
Oct 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 28, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Oct 15, 2026UBS
INITIATE
INITIATEBuy

Insider ledger

Form 4
$54.6M
bought · 1 insider
$892.6K
sold · 8 insiders
−53.9%
vs their $6.23 cost
DateInsiderTypeValue
Oct 5, 2026
CORRIGAN MARK
Director
Oct 5, 2026
AWARD10,700 sh
Oct 5, 2026
CORRIGAN MARK
Director
Oct 5, 2026
AWARD64,000 sh
Oct 5, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Oct 5, 2026
AWARD10,700 sh
Oct 5, 2026
HENRY CHRISTIAN O
Director
Oct 5, 2026
AWARD10,700 sh
Oct 5, 2026
Verdine Gregory L.
Director
Oct 5, 2026
AWARD10,700 sh
Oct 5, 2026
HENRY CHRISTIAN O
Director
Oct 5, 2026
AWARD64,000 sh
Oct 5, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Oct 5, 2026
AWARD64,000 sh
Oct 5, 2026
Rawcliffe Adrian
Director
Oct 5, 2026
AWARD10,700 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
20,649,846
shares short
-2.5%
vs prior settlement
6.8
days to cover
≈10.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 Press
Wave Life Sciences presented Phase 1 data for WVE-007, an siRNA targeting INHBE for obesity, at ObesityWeek 2026. The…
Impact 4/10
Nov 13, 2026 FDA
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composi
Oct 27, 2026 SEC
BlackRock filed a Schedule 13G disclosing a 6.8% passive stake in Wave Life Sciences as of September 30, 2026…
SC 13G · Impact 4/10
Oct 27, 2026 SEC
BlackRock filed an amended Schedule 13G reporting a passive stake in Wave Life Sciences as of September 30, 2026. The…
SC 13G/A · Impact 2/10
Oct 27, 2026 SEC
Wave Life Sciences reported Q3 2026 revenue of $13.2M (up 73% YoY from $7.6M) and a GAAP net loss of $61.9M ($-0.30…
8-K · Impact 6/10
Oct 5, 2026 Insider
CORRIGAN MARK was granted 10,700 shares
Director
Oct 5, 2026 Insider
CORRIGAN MARK was granted 64,000 shares
Director
Oct 5, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. was granted 10,700 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 13, 2026
FDA
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composition by inducing fat loss without muscle loss…
Nov 11, 2026
Press release
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…
Nov 9, 2026
Earnings date
WVE Q3 2026 Earnings Scheduled · 2026-11-09
Oct 27, 2026
Earnings
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on…
Oct 19, 2026
Press release
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…

SecBot reports

12 filings · 4 press releases · 3 bullish · 0 bearish · 1 mixed · 8 neutral
All WVE filing & press-release reports (16)